China BioPharma Appoints Dr. Yimin Yu, Current Chairman of HYTE Research to Advisory Board.ISELIN, N.J. -- Techedge Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :TEDG) announced that China BioPharma, Ltd. has appointed Dr. Yimin Yu, the current Chairman of HYTE Research, LLC to the company's Board of Advisors. Peter Wang commented, "Dr. Yu brings substantial experience to our Board of Advisors in the areas of technology transfer and cGMP (current good manufacturing practices), which are used by pharmaceutical manufacturers as they produce and test products for human use." "As a member of our Board of Advisors, Dr. Yu will be extremely helpful in China BioPharma's focus in developing our current portfolio of vaccines and research products covering such areas as highly pathogenic viruses and cancer drugs. Dr. Yu also brings extensive experience in patent infringement theory, and will provide a helpful advisor on preserving China BioPharma's vaccine and drug patent rights for our portfolio of products" Peter Wang, CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Techedge. Dr. Yimin Yu has been serving as the Chairman of HYTE Research, LLC since 2005, and served as Senior Research Chemist at Church and Dwight Church & Dwight Co., Inc. (NYSE: CHD) is a major U.S. manufacturer of household products that is based in Princeton, New Jersey. While it manufactures many items, it is by far best known for its Arm & Hammer line which includes baking soda and many other items made with it. Inc. from 2001-2005. Dr. Yu was instrumental in developing alternative approaches in product development through his years of product array analysis, as well as technology transfer and validation. From 1992 to 2001, Dr. Yu served as the Section Manager of Manufacturing Technical Support for Wampole, Carter-Wallace, Inc., where he developed Enzyme-Linked Immunosorbent immunosorbent /im·mu·no·sor·bent/ (-sor´bent) an insoluble support for antigen or antibody used to absorb homologous antibodies or antigens, respectively, from a mixture; the antibodies or antigens so removed may then be eluted in pure Assay's (ELISA ELISA (e-li´sah) Enzyme-Linked Immuno-Sorbent Assay; any enzyme immunoassay using an enzyme-labeled immunoreactant and an immunosorbent. ELISA n. ) for the detection of hCG for pregnancy tests (0.3ng/mL vs. 2ng/mL), as well as a reduced process to check the purity of Rubella virus (1 hour assay vs. 5 hour electrophoresis). Dr. Yimin Yu received his Bachelor of Science Noun 1. Bachelor of Science - a bachelor's degree in science BS, SB bachelor's degree, baccalaureate - an academic degree conferred on someone who has successfully completed undergraduate studies in Biophysics biophysics, application of various methods and principles of physical science to the study of biological problems. In physiological biophysics physical mechanisms have been used to explain such biological processes as the transmission of nerve impulses, the muscle at Fudan University in Shanghai, China, and Ph.D in Biophysical and Biochemical Sciences, specializing in immunology at the University of Houston in Houston, Texas. About China BioPharma China BioPharma is a wholly owned subsidiary Wholly Owned Subsidiary A subsidiary whose parent company owns 100% of its common stock. Notes: In other words, the parent company owns the company outright and there are no minority owners. of Techedge Inc, which owns majority rights to Tianyuan Bio-Pharmaceutical Co., Ltd., established in 1989, is one of China's largest non-governmental owned vaccine research manufacturers and is the first in China confirmed to GMP GMP (guanosine monophosphate): see guanine. standard. The company's current products consist of vaccines for epidemic hemorrhagic fever epidemic hemorrhagic fever n. An acute viral hemorrhagic fever characterized by headache, high fever, sweating, thirst, photophobia, coryza, cough, myalgia, arthralgia, and abdominal pain with nausea and vomiting. (Ebola) and influenza with high reputation and market-occupying rate. The vaccines for both epidemic hemorrhagic fever and influenza virus have been awarded the National New Product Prize and National Tech Progress Prize. With its recently completed production facility that is the largest and best human-vaccine production facility in China, it is also the nation's main vaccine production base whenever there is an epidemic disease outbreak in the region, such as SARS, and avian H5N1 influenza (bird flu). About Techedge Inc. The Company has recently repositioned itself to focus at opportunities in the fast growing bio-paceutical sector in China. For more information, please visit its website at www.techedgeinc.net. FORWARD-LOOKING STATEMENT DISCLAIMER Some of the statements made in this press release discuss future events and developments, including our future business strategy and our ability to generate revenue, income and cash flow, and should be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. These "forward-looking" statements can generally be identified by words such as "expect," "anticipate," "believe," "estimate," "intend," "plan," and similar expressions. These statements involve a high degree of risk and uncertainty that exists in the Company's operations and business environment and are subject to change based on various factors that could cause actual Company results, performance, plans, goals and objectives to differ materially from those contemplated or implied in these forward-looking statements. Actual results may be different from anticipated results for a number of reasons, including the Company's new and uncertain business model, uncertainty regarding acceptance of the Company's products and services and the Company's limited operating history. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion